Recent Quotes (30 days)

You have no recent quotes
chg | %

Aurinia Pharmaceuticals Inc  

(Public, TSE:AUP)   Watch this stock  
Find more results for TSE:ISA
-0.15 (-3.26%)
Oct 26 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 4.43 - 4.89
52 week 2.23 - 7.50
Open 4.50
Vol / Avg. 39,180.00/103,569.00
Mkt cap 154.06M
P/E     -
Div/yield     -
EPS -0.69
Shares 36.55M
Beta 3.18
Inst. own     -
Nov 11, 2016
Q3 2016 Aurinia Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Sep 28, 2016
Aurinia Pharmaceuticals Inc at Leerink Partners Rare Disease & IO Roundtable Series - Webcast
Sep 12, 2016
Aurinia Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
Aug 5, 2016
Q2 2016 Aurinia Pharmaceuticals Inc Earnings Release

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -5956.36% -7917.87%
Operating margin -8276.36% -10034.04%
EBITD margin - -9371.06%
Return on average assets -45.36% -43.30%
Return on average equity -73.89% -69.13%
Employees 26 -
CDP Score - -


1203-4464 Markham St
+1-250-7084272 (Phone)
+1-250-7442498 (Fax)

Website links


Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

Officers and directors

Richard M. Glickman LL.D. Executive Chairman of the Board
Age: 57
Charles A. Rowland Jr. Chief Executive Officer, Director
Age: 57
Dennis Bourgeault Chief Financial Officer, Corporate Secretary
Michael R. Martin Chief Operating Officer
Neil Solomons M.D. Chief Marketing Officer
Celia Economides Associate Vice President, Corporate Communications & Patient Advocacy
Robert B. Huizinga Vice President - Clinical Affairs
Lawrence D. Mandt Vice President - Regulatory and Quality
Age: 57
Benjamin Rovinski Ph.D. Independent Director
Age: 58